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Brown adipose tissue, where Uncoupling Protein 1 (UCP1) activity uncouples mitochondrial respiration, is an important site
of facultative energy expenditure. This tissue may normally function to prevent obesity. Our aim was to investigate by sequence
analysis the presence of UCP1 gene variations that may be associated with obesity. We studied 100 severe obese adults (BMI
> 40kg/m2) and 100 normal-weight control subjects (BMI range = 19–24.9kg/m2). We identiﬁed 7 variations in the promoter
region, 4 in the intronic region and 4 in the exonic region. Globally, 72% of obese patients bore UCP1 polymorphisms. Among
UCP1 variants, g.IVS4−208T>G SNP was associated with obesity (OR: 1.77; 95% CI = 1.26–2.50; P = .001). Further, obese
patients bearing the g.−451C>T (CT+TT) or the g.940G>A (GA+AA) genotypes showed a higher BMI than not polymorphic
obese patients (P = .008 and P = .043, resp.). In conclusion, UCP1 SNPs could represent “thrifty” factors that promote energy
storage in prone subjects.
1.Introduction
Brown adipose tissue (BAT) plays an important role in
energy expenditure [1]. Its thermogenic activity requires not
only the presence of a dense vascularisation and sympathetic
innervation, but also the expression of Uncoupling Protein 1
(UCP1) [2, 3]. UCP1 is localized on the inner mitochondrial
membrane where it uncouples oxidative metabolism from
ATP synthesis, resulting in the dissipation of energy through
the release of heat [4]. In humans, BAT exerts its function
especially during the ﬁrst years of life and decreases with age
[5]. However, several metabolic active depots of BAT have
been recently demonstrated also in adult humans [6–8]. It
has been calculated that BAT malfunction could lead to a
weight gain of 1-2kg/yr [9]. These data suggest that BAT
speciﬁc proteins, such as UCP1, could be involved in obesity
onset so representing a possible target of pharmaceutical
interventionsinthisﬁeld[10,11].Inthelastyears,UCP1loss
has been associated with obesity susceptibility in UCP1−/−
mice, particularly during aging and a high-fat diet [12,
13]. We previously described the association between the
variation −3826A>G in the UCP1 promoter and a severe
fatty liver steatosis during obesity [14] .T h ea i mo ft h i ss t u d y
was to search for further gene alterations associated with
obese phenotype in the UCP1 gene (ENSG00000109424) by
sequence analysis.2 Journal of Obesity
Table 1: General and biochemical characteristics of obese patients
and control subjects.
Obese patients Control subjects
(n = 100) (n = 100)
Females (%) 60 64
Age (years) 32.1 ± 10.93 3 .3 ±8.1
BMI∗ (kg/m2)4 7 .9 ±6.92 2 .8 ±2.1
Adiponectin∗ (μg/mL) 31.6 ± 30.05 3 .8 ±38.6
Leptin∗ (ng/mL) 119.6 ±72.42 1 .9 ±18.7
Resistin (ng/mL) 12.2 ±8.41 2 .7 ±7.9
Glucose∗ (mmol/L) 4.9 ± 0.84 .5 ±0.4
Total cholesterol (mmol/L) 4.7 ± 1.15 .0 ±0.7
Triacylglycerols∗ (mmol/L) 1.5 ± 0.60 .9 ±0.3
AST∗ (U/L) 26.5 ± 16.71 9 .8 ±5.6
ALT∗ (U/L) 39.8 ± 35.02 2 .5 ±12.9
GGT∗ (U/L) 35.3 ± 26.01 7 .4 ±10.4
Creatinine (mg/dL) 0.9 ± 0.20 .7 ±0.1
∗Statistically signiﬁcant diﬀerence between obese and control subjects, P<
.001 at Mann-Whitney test. Biochemical parameters were measured by
routine laboratory methods. Adipokines concentrations were measured by
ELISA assay (LINCO Research, Mo, USA). Values are expressed as mean ±
SD.
2.MaterialsandMethods
We studied 200 age-matched unrelated Caucasian subjects
from Southern Italy: 100 adult severe obese patients (60%
female, mean ± SD: BMI = 47.9 ± 6.9kg/m2;a g e=
32.1 ± 10.9 years) and 100 unrelated adult normal-weight
subjects (64% female, mean ± SD: BMI = 22.8 ± 2.1kg/m2;
age = 33.3 ± 8.1 years). The patients were recruited at the
obesity outpatient clinic of the Department of Clinical and
Experimental Medicine, University of Naples Federico II,
Italy, from 2007 to 2008, whereas control subjects were
recruited at the Department of Preventive Medical Science
of the Federico II University Hospital. Clinical and bio-
chemical data were obtained from each patient on their ﬁrst
admission. The general and biochemical characteristics of
the studied populations are reported in Table 1.A l lp a t i e n t s
and controls gave their informed consent to the study, which
was carried out according to the Helsinki II Declaration. The
research was also approved by the Ethics Committee of the
School of Medicine, University of Naples Federico II.
Genomic DNA was extracted from whole blood (Nucl-
eon BACC-II; Amersham Science Europe). UCP1 5  ﬂank-
ing region, exons and intron-exon junction regions were
ampliﬁed by ten sets of primers (primers ID: RSA000984680,
RSA000984677, RSA000984675, RSA000984673, RSA00098
4666, RSA000990288, RSA000990284, RSA000990283, RSA0
00990281,andRSA000990278http://www.ncbi.nlm.nih.gov/
sites/entrez). PCR products were sequenced on ABI Prism
3130 Genetic Analyzer (Applied Biosystems, Foster City,
CA). PCR conditions were 96◦Cf o r5m i n ;t h a n9 4 ◦Cf o r3 0
sec, 60◦C for 45 sec and 72◦C for 45 sec, for 40 cycles; ﬁnal
extension at 72◦C for 10 min; ﬁnal soak at 25◦C.
The mean value and the standard deviation (SD) were
calculated for each investigated parameter. The Mann-
Whitney test and/or χ2, when necessary, were used for
between-group comparisons. Diﬀerences were considered
signiﬁcant at P level <.05. Linkage analysis was performed
by using Haploview 4.0 software [15]. Binomial logistic
regression analysis was used to investigate the association
between the biochemical and genetic characteristics (i.e.,
glucose, total cholesterol and triacylglycerols concentrations
and AST activity; g.−451C>T, g.940G>A, g.IVS4−208, and
g.6537A>T polymorphisms) and the condition of being
obese, after adjustment for age and sex.
Statistical analyses were carried out with the PASW
package for Windows (Ver.18; SPSS Inc. Headquarters,
Chicago, Ill).
3. Results and Discussion
Adiponectin and leptin concentrations were statistically dif-
ferent (P<. 001) between obese and control subjects (mean
level ± SD respectively: adiponectin 31.6±30.0μg/mL ver-
sus 53.8 ± 38.6μg/mL; leptin 119.6 ± 72.4 versus 21.9 ±
18.7ng/mL). Higher concentrations or activities of glucose,
triacylglycerols, AST, ALT and GGT were measured in obese
patients than in controls (P<. 001) (Table 1).
We identiﬁed 15 sequence variations in UCP1 gene
(Table 2): 7 in the promoter region (3/7 described for the
ﬁrst time), 4 in the intronic regions (1/4 described for the
ﬁrst time) and 4 in the exonic regions (2 in the 5  UTR; 2 in
the translated region). Globally, 72% of obese patients bore
one or more UCP1 polymorphisms.
There were no diﬀerences in genotype frequencies
between obese and control subjects at level of the detected
SNPs, except for g.IVS4−208T>G polymorphism more
frequent in obese than in control subjects (P = .002). After a
permutation test with 100000 permutations, the association
ofthepolymorphicallelewiththeobesephenotyperemained
statistically signiﬁcant (P = .017). Subjects bearing this
polymorphism(TGorGG)wereathighriskforobesity(OR:
1.774; 95% CI = 1.26–2.50, P = .001). At binomial logistic
regression analysis, the g.IVS4−208 (TG+GG) genotype
was conﬁrmed to be statistically associated in our patients
with obesity independently of sex and age (OR: 22.0; 95%
CI = 5.6–87.1). This SNP did not alter the splicing site
nor the branch site [16, http://www.umd.be/HSF/], and
the polymorphic allele did not change the ΔG of the
predicted mRNA secondary structure by mfold analysis
(http://mfold.bioinfo.rpi.edu), suggesting that the stability
of the polymorphic mRNA is the same as the wild-type.
The G allele may be a marker linked to other gene variants
p r o m o t i n ge n e r g ys t o r a g ea sw e l la sf a ta c c u m u l a t i o ni n
prone subjects.
The novel UCP1 variants g.−637T>C, g.−206C>A, and
g.IVS2+174T>A, each of them present in a single obese
patient, were not associated with diﬀerences in clinical
and/or biochemical parameters measured in the obese and
control populations. Among them, only the g.−206C>A
occurred in a conserved region indentiﬁed by cisRED algo-
rithm (http://www.cisred.org/)a sacis-regulatory elementJournal of Obesity 3
Table 2: UCP1 sequence variations and their frequencies in obese and control subjects.
Polymorphisms Obese patients Control subjects
n = 100 n = 100
Position rs# wt HE HO wt HE HO
g.−637T>C1 99 1 0 100 0 0
g.−451C>T rs36207410 82 16 2 86 14 0
g.−412A>C rs3811787 57 36 7 49 43 8
g.−372A>C rs1800660 97 3 0 97 3 0
g.−206C>A1 99 1 0 100 0 0
g.−56C>T rs3749539 91 9 0 90 10 0
g.−17C>G1 94 6 0 94 6 0
g.12A>C rs10011540 91 9 0 90 10 0
g.21G>A rs1800661 86 13 1 79 21 0
g.940G>A (p.A64T) rs45539933 92 8 0 91 9 0
g.IVS2+138C>T rs7688743 80 15 5 70 27 3
g.IVS2+174T>A1 99 1 0 100 0 0
g.IVS2+201T>G rs2071416 79 21 0 77 22 1
g.IVS4−208T>G2 rs1494808 45 44 11 69 23 8
g.6537A>T (p.M229L) rs2270565 89 11 0 87 13 0
1New variants; 2More frequent polymorphism in obese patients (P = .002) than in controls. wt: wild-type homozygous subjects; HE: heterozygous and HO:
homozygous subjects at level of the detected variant.
(craHsap157022), and we could hypothesize to alter the
interaction with transcriptional factors.
Regarding the previously described UCP1 polymor-
phisms, a higher mean BMI was observed in our obese
patients bearing the g.−451C>T (CT+TT) than in not
polymorphic obese patients (resp., 52.6 ± 7.4kg/m2 versus
47.0 ± 6.6kg/m2, P = .008).
The amino acidic substitution p.M229L (g.6537A>T) in
the ﬁfth helix of the protein is due to an A>T transversion in
the5thexonoftheUCP1gene[17].Moriandcolleagues[18]
found a higher frequency of the Leu allele of the p.M229L
(g.6537A>T) polymorphism in a Japanese obese population
with Type II diabetes, indicating this gene variation as
a diabetes-associated SNP, while other studies failed to
demonstrate such association [9, 19, 20]. In our study we
found that patients carrying the polymorphic allele for the
p.M229L polymorphism showed a slightly higher mean BMI
than the wild-type patients (50.6kg/m2 versus 47.6kg/m2,
resp.) while no diﬀerence were found at level of glucose and
insulin concentration or regarding the homeostatic model
assessment (HOMA) index (a measure of insulin sensitivity)
(data not shown). This diﬀerence could be due to the lower
mean age of our studied subjects (32.1 years in our patients
versus 58.6 years in Mori et al. [18]), since Type II diabetes is
more frequent in middle aged than in young adult patients.
Further, the haplotype investigation by Haploview soft-
ware showed a signiﬁcant linkage disequilibrium among the
three SNPs g.−56C>T (a), g.12A>C (b) and g.940G>A (c)
(a-b: log likelihood ratio, LOD = 27.5; r2 = 1; b-c and a-
c: LOD = 22.6; r2 = 0.9); however no statistically signiﬁcant
associationwasobservedbetweenobesityandthishaplotype,
the frequency of this latter being the same in obese and
control subjects (8.0% versus 9.0%, resp.).
The g.12A>C polymorphism is located in the insulin
response sequence (IRS). In in vitro experiments, the DNA
mutated C allele was demonstrated to reduce the transcrip-
tion of UCP1 by 40% respect to the wild-type allele. This
variation was hypothesized to impair the aﬃnity of the
transcription factors for the consensus motif of IRS [18].
Further, this SNP was previously indicated as contributing
to hepatic lipid accumulation and altering insulin sensitivity
in Japanese individuals with Type II diabetes mellitus
(NIDDM) [18]. In our population, the lack of association
of this SNP with any obesity-related phenotype could be
d u et ot h ey o u n g e rm e a na g eo fo u rp a t i e n t sr e s p e c tt o
those investigated by Fukuyama et al. [21] (32.1 years versus
56.6 years, resp.) and to diﬀerent ethnic background of the
studied groups.
The amino acidic substitution p.A64T (g.940G>A) in the
ﬁrst matrix loop of the protein is due to a G>A transition in
the 2nd exon of the UCP1 gene [17].
Cha et al. [22] reported in a Korean female population
an association between the mutated allele and a higher blood
pressure.Inourpopulation,polymorphicpatientscompared
to wild-type patients showed a higher mean BMI (52.0 ±
6.4kg/m2 versus47.5 ±6.9kg/m2,P = .043)butonlyatrend
toward a higher mean systolic blood pressure (130.0mmHg
versus 124.4mmHg, resp.). This diﬀerence does not raise
the statistically signiﬁcant level probably due to the lower
number of patients in our examined casistic.
4. Conclusions
Functional activity of BAT has been recently demonstrated
in adult humans [6–8] and its amount is inversely related to
body fat percentage [23]. We do not have any information4 Journal of Obesity
in our patients about BAT amount. However, variations in
the BAT marker UCP1 gene were present in most of our
obese patients. These variations could represent common
factors contributing to the development of obesity, partic-
ularly, g.−451C>T, g.940G>A, and g.IVS4−208T>Gc o u l d
represent “thrifty” factors that promote energy storage. The
preciseroleinobesityofthesevariantsshouldbeinvestigated
in a larger casistic.
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